Restenosis News and Research

RSS

Restenosis means the reoccurrence of stenosis, a narrowing of a blood vessel, leading to restricted blood flow. Restenosis usually pertains to an artery or other large blood vessel that has become narrowed, received treatment to clear the blockage and subsequently become renarrowed. This is usually restenosis of an artery, or other blood vessel, or possibly a vessel within an organ.

InspireMD announces availability of new delivery system for MGuard stent

InspireMD Ltd. is announcing today the availability of a new and improved delivery system for its MGuard coronary stent system. The new delivery system, which has already been introduced in selected regions around the world, will now make its launch in South America during SOLACI 2010, taking place at the Hilton Hotel in Buenos Aires, Argentina, August 11th-13th.

11 Aug 2010

Boston Scientific initiates enrollment in EVOLVE clinical trial of SYNERGY Coronary Stent

Boston Scientific Corporation today announced the start of patient enrollment in the EVOLVE clinical trial, which is designed to assess the safety and performance of its fourth-generation SYNERGY™ Coronary Stent. The first patient was enrolled by Ian Meredith, M.B.B.S., Ph.D., Professor and Director of MonashHeart, at Monash Medical Centre in Melbourne, Australia.

4 Aug 2010

CSI launches Diamondback Predator 360 catheter system for treatment of peripheral arterial disease

Cardiovascular Systems, Inc. has launched its second-generation product, the Diamondback Predator 360° PAD System, for the treatment of peripheral arterial disease (PAD). The new device uses the same mechanism of action as the clinically proven Diamondback 360 PAD System with improvements in the crowns and shaft for enhanced clinical performance and shorter procedure times.

4 Aug 2010

Bypass better strategy for treating progressive, complex recurrent SFA disease: Study

Researchers from The Methodist Hospital's DeBakey Heart and Vascular Center in Houston, Texas have studied outcomes of patients who had endovascular and open interventions for recurrent superficial femoral artery (SFA) occlusive disease. Results of their work are detailed in the August issue of the Society for Vascular Surgery's® Journal of Vascular Surgery®.

3 Aug 2010

Devax's AXXESS Biolimus A9 Eluting Coronary Bifurcation Stent System receives CE Mark approval

Devax, Inc. announced today the company received CE Mark for its AXXESS™ Biolimus A9® Eluting Coronary Bifurcation Stent System, allowing the company to initiate sales in the European Union and other countries that recognize the CE Mark.

29 Jul 2010

Tryton announces first three implants of Side Branch Stent System in Israel

Tryton Medical, Inc., the leading developer of stents designed to definitively treat bifurcation lesions, announced that the company's TRYTON Side Branch Stent™ System has been used in three cases in Israel for the first time.

24 Jun 2010

OrbusNeich's Genous Bio-engineered R stent shows safety for percutaneous treatment of coronary artery stenosis

OrbusNeich today announced that six-month clinical follow-up data show the safety and efficacy of the combination of pre-dilatation with a paclitaxel drug-eluting balloon (Sequent Please®, B.Braun) followed by implantation of the company's Genous Bio-engineered R stent for the percutaneous treatment of coronary artery stenosis.

22 Jun 2010

Boston Scientific's TAXUS Element Paclitaxel-Eluting Coronary Stent System launched in Europe

Boston Scientific Corporation today announced the market launch and first implants of its TAXUS® Element™ Paclitaxel-Eluting Coronary Stent System in the European Union and other CE Mark countries. The TAXUS Element Stent System is the Company's third-generation drug-eluting stent (DES) technology and incorporates a platinum chromium alloy with an innovative stent design and an advanced catheter delivery system. It received CE Mark approval last month, which included a specific indication for the treatment of diabetic patients.

10 Jun 2010

Spectranetics plans multi-center, randomized clinical trial program for in-stent restenosis

The Spectranetics Corporation today announced its clinical trial plans related to the treatment of in-stent restenosis (ISR) in arteries above the knee, which remains a major unsolved medical problem. There is no device currently cleared or approved by the FDA to treat ISR.

10 Jun 2010

Medtronic’s Resolute zotarolimus-eluting stent as effective as Xience V everolimus-eluting stent: Study

The highly anticipated first results of the RESOLUTE All Comers study were presented today during the late-breaking clinical trial session of the 2010 EuroPCR meeting. In this novel 2,292-patient randomized trial, the Resolute zotarolimus-eluting stent from Medtronic, Inc. was found to be as safe and effective as the Xience® V everolimus-eluting stent from Abbott Laboratories.

26 May 2010

InspireMD announces next generation MGuard Prime net protective Cobalt Chromium stent system

InspireMD, Ltd. announced today the next generation MGuard stent, MGuard Prime(R), a net protective Cobalt Chromium stent system. MGuard Prime(R) offers an advanced patented Cobalt Chromium design, superior flexibility and excellent deliverability on top of the established benefits of the MGuard MicroNet(R) technology.

26 May 2010

NEVO Sirolimus-eluting Coronary Stent demonstrates safety and efficacy outcomes at 12 months

At 12 months the NEVO™ Sirolimus-eluting Coronary Stent has continued to demonstrate excellent safety and efficacy outcomes compared to Taxus® Liberte® according to new data presented today from the NEVO™ RES-I clinical trial. These results were presented as a late breaking trial at EuroPCR, the leading medical conference in Europe for physicians specializing in interventional cardiovascular medicine.

26 May 2010

Medtronic announces clinical data presentations on cardiovascular devices at EuroPCR

Medtronic, Inc., announced today the schedule of important clinical data presentations during EuroPCR, a major cardiology meeting taking place May 25-28 in Paris at the Palais de Congrès.

21 May 2010

BSX receives CE Mark approval for TAXUS Element Paclitaxel-Eluting Coronary Stent System

Boston Scientific Corporation today announced it has received CE Mark approval for its TAXUS Element Paclitaxel-Eluting Coronary Stent System, the Company's third-generation drug-eluting stent technology. This approval includes a specific indication for the treatment of diabetic patients.

13 May 2010

Boston Scientific receives CE Mark approval for TAXUS Element Paclitaxel-Eluting Coronary Stent System

Angiotech Pharmaceuticals, Inc. today announced that its corporate partner, Boston Scientific Corporation, has received CE Mark approval for its TAXUS(R) Element(TM) Paclitaxel-Eluting Coronary Stent System, Boston Scientific's third-generation drug-eluting stent (DES) technology.

13 May 2010

Zilver PTX Drug-Eluting Peripheral Stent safe and effective for treating SFA lesions

Patients treated with the Zilver® PTX™ Drug-Eluting Peripheral Stent maintained clinical improvement at two years, according to interim results from the Zilver® PTX™ Global Registry presented today as a late-breaking clinical trial at the Society for Cardiovascular Angiography and Interventions (SCAI) 33rd Annual Scientific Sessions.

10 May 2010

Tryton Medical widens European availability of Side Branch Stent System

Tryton Medical, Inc., the leading developer of stents designed to definitively treat bifurcation lesions, today announced the launch of the TRYTON Side Branch Stent™ System in Austria, Belgium, Denmark, Ireland, Luxembourg, the Netherlands, Norway, Poland, Portugal, Spain, and the United Kingdom. The stent is used to treat bifurcation lesions, the largest unmet need confronting interventional cardiology.

23 Apr 2010

Magnetically guided nanoparticles for delivering DNA, cells and drugs

Scientists and engineers have used uniform magnetic fields to drive iron-bearing nanoparticles to metal stents in injured blood vessels, where the particles deliver a drug payload that successfully prevents blockages in those vessels. In this animal study, the novel technique achieved better results at a lower dose than conventional non-magnetic stent therapy.

20 Apr 2010

New study may help devise better treatment strategies for cancer and heart disease

Research led by T. Cooper Woods, PhD, Assistant Professor of Pharmacology and Experimental Therapeutics at LSU Health Sciences Center New Orleans, and Director of the Molecular Cardiology Research Laboratory at Ochsner Clinic Foundation, has identified the mechanism of how a drug commonly used on stents to prevent reclosure of coronary arteries, regulates cell movement which is critical to wound healing and the progression of diseases like cancer.

16 Apr 2010

ChemoCentryx undertakes Phase II clinical trial of CCX140

ChemoCentryx, Inc., today announced that it has undertaken a Phase II clinical trial of CCX140, a novel, orally-available small molecule compound designed to specifically target the chemokine receptor known as CCR2.

22 Mar 2010

Restenosis News and Research

Further Reading

InspireMD announces availability of new delivery system for MGuard stent

Boston Scientific initiates enrollment in EVOLVE clinical trial of SYNERGY Coronary Stent

CSI launches Diamondback Predator 360 catheter system for treatment of peripheral arterial disease

Bypass better strategy for treating progressive, complex recurrent SFA disease: Study

Devax's AXXESS Biolimus A9 Eluting Coronary Bifurcation Stent System receives CE Mark approval

Tryton announces first three implants of Side Branch Stent System in Israel

OrbusNeich's Genous Bio-engineered R stent shows safety for percutaneous treatment of coronary artery stenosis

Boston Scientific's TAXUS Element Paclitaxel-Eluting Coronary Stent System launched in Europe

Spectranetics plans multi-center, randomized clinical trial program for in-stent restenosis

Medtronic’s Resolute zotarolimus-eluting stent as effective as Xience V everolimus-eluting stent: Study

InspireMD announces next generation MGuard Prime net protective Cobalt Chromium stent system

NEVO Sirolimus-eluting Coronary Stent demonstrates safety and efficacy outcomes at 12 months

Medtronic announces clinical data presentations on cardiovascular devices at EuroPCR

BSX receives CE Mark approval for TAXUS Element Paclitaxel-Eluting Coronary Stent System

Boston Scientific receives CE Mark approval for TAXUS Element Paclitaxel-Eluting Coronary Stent System

Zilver PTX Drug-Eluting Peripheral Stent safe and effective for treating SFA lesions

Tryton Medical widens European availability of Side Branch Stent System

Magnetically guided nanoparticles for delivering DNA, cells and drugs

New study may help devise better treatment strategies for cancer and heart disease

ChemoCentryx undertakes Phase II clinical trial of CCX140

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News